{"id":"W4296531778","doi":"10.1016/s2152-2650(22)00998-3","title":"Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Classical Hodgkin lymphoma; Refractory (planetary science); Open label; Medicine; Phases of clinical research; Oncology; Internal medicine; Multicenter study; Hodgkin lymphoma; Lymphoma; Dermatology; Clinical trial; Materials science; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001154217,0.0007649583,0.001063275,0.0002793148,0.0003181248,0.0008393319,0.0005631502,0.000895291,0.01000464],"category_scores_gemma":[0.0006982803,0.0003217465,0.0007995197,0.0001853961,0.0004098477,0.0006960263,0.0002169226,0.002438484,0.00183115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005269086,"about_ca_system_score_gemma":0.00062295,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006744023,"about_ca_topic_score_gemma":0.001862321,"domain_scores_codex":[0.9997665,0.00009436556,0.00001209665,0.00004184604,0.00003624168,0.00004903906],"domain_scores_gemma":[0.9996575,0.00008334761,0.00006780113,0.00002215624,0.00002993386,0.0001393204],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4640677,0.02379775,0.007993308,0.001540218,0.002516855,0.0004033356,0.000336029,0.002008981,0.07953654,0.0005329603,0.04068031,0.376586],"study_design_scores_gemma":[0.5931523,0.3059427,0.05112,0.0001616302,0.002293826,0.0009525154,0.0001317226,0.002695117,0.01394905,0.0004359806,0.02903339,0.0001319326],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9694717,0.01198466,0.001242453,0.002409254,0.0007636793,0.001353779,0.004376069,0.0005167131,0.0078816],"genre_scores_gemma":[0.9751517,0.00437571,0.002408541,0.003074328,0.0006579916,0.0005705989,0.00432348,0.0001015492,0.00933616],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01000464,"threshold_uncertainty_score":0.03346884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05618524231538953,"score_gpt":0.3878656953872834,"score_spread":0.3316804530718939,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}